



# Neuroprotectives: Herbs vs Heterocyclics

Divya Dhawal Bhandari,<sup>1</sup> Prabhjot Kaur,<sup>2</sup> Hitesh Chopra,<sup>3</sup> Suman Lata<sup>4</sup>

## Abstract

Neurodegenerative diseases are described as the ones associated with the loss of any specific nerve function which results in either cell death or abnormal functioning of associated organ such as memory loss, tremors, difficulty in speaking and walking, loss of senses and numbness. A number of heterocyclic nuclei containing compounds are available in the market to treat neurodegenerative disorders and associated symptoms due to their concerned therapeutic potential. Ongoing research on these heterocyclics have confirmed their tremendous potential towards the treatment of neurodegenerative diseases. Although a number of heterocyclic containing compounds are already there in the market against various neurodegenerative diseases, but till date no specific treatment is available against any of the neurodegenerative disease, thus opening new area of research. Herbs are emerging as new area of research due to their wide availability and with lesser or no side effects. These days researchers are gaining interest towards the development of newer neurodegenerative agents derived from plants. This review is focused towards the comparison of various available herbs, heterocyclics and the compounds under clinical trials, against neurodegenerative diseases primarily focusing on Parkinson disease and multiple sclerosis.

**Key words:** Central nervous system; Peripheral nervous system; Herbal medicine; Parkinson disease; Multiple sclerosis.

1. University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
2. Chandigarh College of Pharmacy, Landran, Mohali, Punjab, India.
3. Department of Biosciences, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India.
4. ASBASJSM College of Pharmacy, Bela, Ropar, Punjab, India.

**Citation:** —

Bhandari DD, Kaur P, Chopra H, Lata S. Neuroprotectives: herbs vs heterocyclics. Scr Med. 2025 May-Jun;56(3):567-78.

**Corresponding author:**


PRABHJOT KAUR  
E: prabhozia28@gmail.com

Received: 22 October 2024  
Revision received: 8 January 2025  
Accepted: 9 January 2025

## Introduction

Parkinson disease (PD) is an age-related neurological illness that progresses over time and has an unknown cause.<sup>1</sup> Degeneration of the dopaminergic nigrostriatal system in the subthalamic nucleus, *globus pallidus* (internal and exterior segments), *striatum*, *substantia nigra pars compacta* and *substantia nigra pars reticulata* are its defining characteristics.<sup>1, 2</sup> In order to generate appropriate movement, planning, execution and locomotion, these areas are engaged in processing sensory-motor information.<sup>2</sup> Bradykinesia, rigidity, postural irregularities, resting tremors and some non-motor characteristics are among the disease's symptoms.<sup>3</sup> Unlike Alzheimer's dis-

ease and PD, multiple sclerosis (MS) affects mostly the young women usually at the age of 20-40 years.<sup>4</sup> Although MS is idiopathic but genetic and environmental risk factors influence the disease susceptibility.<sup>5</sup> MS is an autoimmune inflammatory disease where autoantibodies kill oligodendrocytes, the myelin-producing neuroglia of the CNS causing demyelination of neurons, hence axons remain unprotected leading to abnormal impulse transmission to the effector organs (Figure 1). The symptoms of the disease include paralysis, numbness or partial loss of sensation, diplopia and loss of spinal cord reflexes which include urination and defecation.



**Figure 1:** Occurrence of inflammation in multiple sclerosis

BBB: blood-brain barrier; CNS: central nervous system; IFN- $\gamma$ : interferon gamma; IL: interleukin;

## Management of neurodegenerative diseases by herbs

Currently, neurodegenerative diseases are not curable, so the treatments being used are working as a supportive therapy which manages the sign and symptoms, or silence the progression of the disease.

## Management of Parkinson disease

The strategy for treating PD is emphasised on optimising the level of dopamine, by administration of a dopamine precursor levodopa or L-DOPA (L-3, 4-dihydroxyphenylalanine).<sup>6, 7</sup> L-DOPA offers short-term benefit by slowing the progression of the disease, but long-term benefits are unlikely.<sup>8</sup> When L-DOPA is given concomitantly with peripheral decarboxylase inhibitor (like carbidopa), the side effects of L-DOPA, including cardio-vascular and gastro-intestinal problems are alleviated.<sup>7</sup> One more therapeutic approach is about using monoamine oxidase B (MAO-B) inhibitors.

MAO-B enzyme activity is increased during dopamine metabolism which lifts oxidative stress and mitochondrial dysfunctions.<sup>7</sup> Nowadays, the natural extracts from medicinal plants are under study which are showing beneficial pharmacological activities against PD.<sup>9</sup> The reactive oxygen species (ROS) in mitochondria are considered as the key target and molecular mechanism of these medicinal products.<sup>10-12</sup>

### *Acanthopanax senticosus*

Ethanol extract of *Acanthopanax senticosus* (Rupr et Maxim) Harms dried roots and rhizomes (80 %) found to have protective effect on dopaminergic neurons in mice model of PD.<sup>13</sup> The stem bark of *A senticosus* Harms is also effective on *in vivo* model of PD.<sup>14</sup> A 100 % ethanol and 50 % hydroalcoholic extract had preventive effect on MPTP-induced PD in rats and increased the level of dopamine (DA) and noradrenaline (NA) in PD rat model. Sesamin and eleutheroside B, two bioactive substances from *A senticosus*, have anti-PD action. In the rotenone-induced rat model, sesamine had a preventative impact on behavioural dysfunction and pivomolar dosages of sesamine shielded neuronal pheochromocytoma cells (PC)-12 from cellular death brought on by methyl phenyl pyridinium (MPP+).<sup>15</sup>

### *Albizia adianthifolia*

A common medicinal plant in Cameroon and Africa is *Albizia adianthifolia*. Its aqueous extract demonstrated anti-PD action at dosages of 150 mg/kg and 300 mg/kg by increasing superoxide-dismutase (SOD), glutathione-peroxidase (GPX) and glutathione (GSH) levels and decreasing protein carbonyl and malondialdehyde (MDA) levels.<sup>16</sup>

### *Allium sativum*

An ethanolic extract of *Allium sativum* demonstrated considerable anti-PD activity at the doses of 200 mg/kg and 400 mg/kg in haloperidol induced PD in rats. In a subacute MPTP PD model in mice, the bioactive S-allylcysteine component of *A sativum* reduced the production of tumour necrosis factor (TNF)- and inducible nitric oxide synthase (NOS).<sup>17,18</sup>

### *Alpiniae oxyphyllae*

The dried, ripe seeds of *Alpiniae oxyphyllae* have a protective effect on PC12 cells and dopaminergic neurons in zebrafish against 6-OHDA- induced PD model.<sup>19</sup> Additionally, it lessens the cell death brought on by H<sub>2</sub>O<sub>2</sub> or sodium nitroprusside in PC12 cells and inhibits apoptotic morphology and lowers tyrosine hydroxylase (TH) expression and cytotoxicity in PC12 cells treated with MPP+.<sup>20</sup>

### *Berberis aristata*

*Berberis aristata* methanolic extract demonstrated strong anti-PD efficacy against 6-OHDA- induced rat model by decreasing lipid peroxidation (LPO) and increasing levels of superoxide dismutase (SOD), catalase (CAT), glutathione and total thiols.<sup>21,22</sup>

### *Beta vulgaris*

The plant *Beta vulgaris* is commonly known as beetroot. In various Parkinson's models, including reserpine- induced model, haloperidol- induced catalepsy and tacrine- induced vacuous chewing movements in rats, pretreatment with methanolic extract of *B vulgaris* showed potent anti-PD effect at doses of 200 mg/kg and 300 mg/kg by reducing LPO level and restoring the protective antioxidant enzymes SOD and CAT in rat brain.<sup>23</sup>

### *Carthamus tinctorius*

Safflower or *Carthamus tinctorius*, is an annual herbaceous plant with many branches that resem-

bles a thistle and is a member of the *Asteraceae* genus. Kaempferol 3-O-rutinoside (K3R) and anhydrosafflor yellow B (AYB), two compounds isolated from safflower, can protect PC12 cells from rotenone- induced neurotoxicity by decreasing the shrinkage of the cell body and H<sub>2</sub>O<sub>2</sub>-induced reactive oxygen species while also restoring TH activity. In a mouse model of PD caused by MPTP, safflower flavonoid extracts have also shown a neuroprotective effect. The standardised flavonoid extract of safflower (SAFE) was used to test the anti-PD impact against a 6-OHDA-induced rat model which further demonstrated anti-PD effect by suppressing synuclein overexpression as well as reactive astrogliosis.<sup>24,25</sup>

### *Cassia obtusifolia*

An 85 percent ethanol extract of this seed has been shown to significantly buffer DA neuronal degeneration brought on by MPTP in the PD mouse model. Strong peroxynitrite- scavenging action is exhibited by alaternin, a component isolated from *C tora*.<sup>26</sup>

### *Elaeocarpus ganitrus*

*Elaeocarpus ganitrus* is traditionally used for prayer beads in Hinduism and Buddhism. Its ethanolic extract showed neuroprotective activity against haloperidol induced PD mice model. Extract exerts neuroprotective effect by decreasing the malondialdehyde (MDA) levels and increasing level of GSH.<sup>27</sup>

### *Evolvulus alsinoides*

The ethanolic extract of *Evolvulus alsinoides* showed potent antioxidant activity and no toxic effects on the viability of PC12 cells. The methanolic extract of roots of *E alsinoides* has anti-dyskinetic activity in acute reserpine-induced dyskinetic rats.<sup>28</sup>

### *Gardenia jasminoides*

*Gardenia jasminoides* Ellis, an evergreen flowering plant belonging to the family *Rubiaceae*, contains geniposide as an active component extracted from the fruit. Geniposide exert anti-PD activity against MPTP mouse model by restoring number of dopaminergic neuron in *substantia nigra pars compacta*. Geniposide also exerted neuroprotection *in-vitro* in SH-SY5Y human neuroblastoma cell lines against MPP+ induced neurotoxicity by reducing the level of  $\alpha$ - synuclein protein in brain.<sup>29</sup>

### Hypericum perforatum

*Hypericum perforatum* L, its methanolic extract has neuromodulating effect against MPTP-induced mouse model of PD. A flavonoid rich extract of *H perforatum* L has protective effects on PC12 cells against apoptosis induced by  $H_2O_2$ .<sup>30,31</sup>

### Magnolia officinalis

Magnolol, a bioactive compound isolated from the bark of *Magnolia officinalis*, exhibited neuroprotective activity against 6-OHDA induced PD in mice by decreasing the levels of TH protein expression in *striatum*.<sup>32</sup>

### Morus alba

A 70 % ethanolic extract of mulberry fruit protect SH-SY5Y cells from 6-OHDA induced stress. Mulberry fruit extract showed a preventive effect

against PD-like symptoms (bradykinesia) in the sub-acute mouse PD model induced by MPTP.<sup>33</sup>

### Tinospora cordifolia

Ethanol extract of *T cordifolia* (TCEE) exhibited significant neuroprotection by increasing the levels of dopamine and complex I in 6-OHDA lesion rat model of PD.<sup>34</sup>

### Uncaria rhynchophylla (URH)

Aqueous extract of URH, tested in PC12 cells stressed by 6-OHDA, reduced the cell death, increased level of GSH, generated ROS and inhibited caspase-3 activity. Post-treatment with URH showed reduction in apomorphine- induced rotation and also lowered dopaminergic neuronal loss in *substantia nigra pars compacta*.<sup>35</sup> The list of known medicinal plants used for PD is summarised in Table 1.

**Table 1:** List of medicinal herbs for management of Parkinson disease

S/N	Name of plant/ Family	Common name	Chemical constituent	Actions performed	References
1	<i>Bacopa monnieri/ Plantaginaceae</i>	Brahmi or waterhyssop	Bacoside and bacopaside	<ul style="list-style-type: none"> <li>Enhance perception, improves mitochondrial functions, diminish a-synuclein accumulation and apoptosis.</li> </ul>	[13-15]
2	<i>Mucuna pruriens/ Fabaceae</i>	Velvet bean	Levodopa, glycoside and glutathione	<ul style="list-style-type: none"> <li>Enhance behavioural and locomotor activity, ease oxidative stress and metal chelating. Support mitochondrial and synaptic function.</li> </ul>	[16], [17]
3	<i>Withania somnifera/ Solanaceae</i>	Ashwagandha	Withanolide and Withaferin	<ul style="list-style-type: none"> <li>Enhance locomotor activities.</li> <li>Adjust dopamine, glutathione and tyrosine hydroxylase expression.</li> <li>Delay iNOS activity and reduce oxidative stress.</li> </ul>	[10], [18], [19]
4	<i>Curcuma longa/ Zingiberaceae</i>	Turmeric	Curcumin	<ul style="list-style-type: none"> <li>Adjust the levels of dopamine and acetylcholine and manage the actions of glutathione peroxidase and superoxide dismutase. Lifting mitochondrial roles and production of adenosine triphosphate.</li> <li>Hinder a-synuclein fibrillation and oxidative stress.</li> </ul>	[7], [20], [21]
5	<i>Ginkgo Biloba/ Ginkgoaceae</i>	Maidenhair tree	Ginkgolide B, EGB 761	<ul style="list-style-type: none"> <li>Adjust the level of dopamine, maintain behaviour and muscle harmonisation.</li> <li>Lifting mitochondrial role and production of adenosine triphosphate.</li> </ul>	[18], [22], [23]
6	<i>Camellia sinensis/ Theaceae</i>	Green tea	Polyphenol and catechins classes: epicatechin, epigallocatechin	<ul style="list-style-type: none"> <li>Redox equilibrium, constrain path of reactive oxygen species-nitric oxide and metal chelating, guards dopaminergic neurons.</li> </ul>	[19], [24], [25]
7	<i>Camellia sinensis/ Theaceae</i>	Black tea	Theaflavins: theaflavin (tf1)	<ul style="list-style-type: none"> <li>Neuron protection, redox preservative, enhances tyrosine hydroxylase, expression of dopamine transporter, diminish apoptosis.</li> </ul>	[16], [18]

8	<i>Scutellaria baicalensis/ Lamiaceae</i>	Baicalein	Flavonoids: wogonin, baicalein, oroxylin and wogonoside	• Anti-inflammatory, antioxidant, inhibit glutamate neurotoxicity, protect chondriosomes.	[36]
9	<i>Panax ginseng/ Araliaceae</i>	Ginseng	Ginsenosides	Improve behavioural defects, improve loss of dopaminergic neurons, neuroprotective.	[7]

## Management of multiple sclerosis

The treatment of MS has three approaches, namely; acute relapses treatment; symptomatic treatment and disease management (treat exacerbations). Along with these, there is a nutritional therapy and other therapies like exercises, physical and speech therapies. The herbs which are used for MS can be categorised into herbal medicine, food and spices and are summarised in

Table 2.<sup>11</sup> The usage of essential oil as an aromatherapy is helpful in pain management, improving health and well-being. Therefore, aromatherapy could be used as a method of symptomatic relieve in MS patients due to its ability to serve in sleep, relaxation, movement of joints and muscles, and enhancement of well-being.<sup>12</sup>

**Table 2:** List of medicinal herbs for management of multiple sclerosis

S/N	Name of plant/ Family	Common name	Chemical constituent	Actions performed	References
1	<i>Hypericum perforatum/ Hypericaceae</i>	St John's wort	Hypericin	• Inhibits depression.	[17]
2	<i>Valeriana officinalis/ Caprifoliaceae</i>	Valerian	Not defined	• Tranquillity via GABA system.	[17]
3	<i>Ginkgo biloba/ Ginkgoaceae</i>	Ginkgo	Ginkgolides	• Reduction of disease exacerbation.	[17]
4	<i>Oenothera biennis/ Onagraceae</i>	Evening primrose oil	γ-linoleic acid	• Involved in breakdown of fatty acids. • Affects lymphocyte activity.	[20], [29], [33], [34]
5	<i>Panax ginseng/ Araliaceae</i>	Ginseng	Ginsenosides	• Active in fighting stress, trauma and fatigue by modulating immunity. • Enhance intelligence, learning and motor activity. • Support neuroprotective activity.	[35]
6	<i>Salvia officinalis/ Lamiaceae</i>	Sage	Polyphenols, essential oils	• Mental improvement, controls mood. • Memory enhancer.	[11], [35]
7	<i>Cannabis/ Cannabaceae</i>	Marijuana	Cannabinoides	• Recovers some symptoms include spasticity, unpleasant feeling, tremor and sadness.	[17]
8	<i>Curcuma longa/ Zingiberaceae</i>	Turmeric	Curcumin	• Reduction of disease exacerbation.	[35]
9	<i>Cinnamomum zeylanicum/ Lauraceae</i>	Cinnamon	Cinnamaldehyde, sodium benzoate	• Management of relapse- remitting experimental autoimmune encephalomyelitis.	[1], [26], [37-41]
10	<i>Crocus sativus/ Iridaceae</i>	Saffron	Crocin	• Diminish clinical symptoms in experimental autoimmune encephalomyelitis mice model. • Overdue onset of illness. • Fight depressed condition.	[34], [35], [38]

11	<i>Nigella sativa/ Ranunculaceae</i>	Black seed	Thymoquinone	• Obstructs oxidative stress. • Helpful in muscle spasticity.	[1], [32], [42]
12	<i>Panax ginseng/ Araliaceae</i>	Ginseng	Ginsenosides	• Anti-inflammatory. • Anti- oxidant. • Neuroprotective.	[43]

## Management of neuro-degenerative diseases by heterocyclics

Last two decades have been marked for the discovery of various novel bioactive moieties by many researchers to get enhanced therapeutic potential with lesser side effects. A number of natural as well as synthetic moieties have emerged as potential candidates to protect neurons against degeneration. Several studies reported the im-

portance of a number of 5- and 6- membered heterocyclics in the treatment of neurodegenerative diseases. Such compounds include pyrrole, purines, pyrimidines, N-heterocyclic compounds (triazolothiadiazoles and triazolothiadiazines) as given in Figure 2.




Figure 2: Various heterocyclics as anti-Parkinson disease drugs




Figure 3: Various targets for heterocyclics against Parkinson disease

BBB: blood-brain barrier; MAO: monoamine oxidase; COMT: catechol-O-methyltransferase;




Figure 4: Various targets for heterocyclics against multiple sclerosis

VCAM-1: vascular cell adhesion protein 1; ALCAM: activated leukocyte cell adhesion molecule; VLA-4: alpha4beta1 integrin; S1PR: sphingosine-1-phosphate receptor;

Table 3: Various heterocyclics under clinical trials against neurodegenerative disorders

NCT number	Study title	Study status	Brief summary	Conditions	Phases	Study type
NCT03841604	Effect of safinamide on Parkinson disease related chronic pain.	Completed	To evaluate the potential efficacy of safinamide 100 mg once daily (OD), compared with placebo, as add-on therapy for Parkinson disease-related chronic pain.	Idiopathic Parkinson disease	4	Interventional
NCT01523301	Rotigotine versus placebo to evaluate the efficacy on depressive symptoms in idiopathic Parkinson disease patients.	Completed	The purpose of this study was to show superiority of rotigotine over placebo on improvement of depressive symptoms in subjects with idiopathic Parkinson disease.	Idiopathic Parkinson disease	4	Interventional
NCT00505687	An open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic Parkinson disease.	Completed	The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic Parkinson disease.	Idiopathic Parkinson disease	3	Interventional
NCT01300819	Placebo-controlled study in patients with Parkinson disease to evaluate the effect of rotigotine on non-motor symptoms.	Completed	The primary objective of this study was to demonstrate that rotigotine improves non-motor symptoms compared to placebo in subjects with Parkinson disease.	Idiopathic Parkinson disease	4	Interventional
NCT01782222	Trial to evaluate the efficacy of rotigotine on Parkinson disease-associated motor symptoms and apathy.	Completed	This trial is being conducted to assess the effects of rotigotine over placebo on improvement of apathy and motor symptoms in subjects with early-stage and advanced stage idiopathic Parkinson disease.	Idiopathic Parkinson disease	4	Interventional

NCT03325556	Relapse prevention study of pimavanserin in dementia-related psychosis.	Completed	The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label pimavanserin treatment.	Dementia-related psychosis	3	Interventional
NCT00322153	Study of the safety and efficacy of memantine in moderate to severe Alzheimer's disease.	Completed	The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).	Dementia of the Alzheimer's type	3	Interventional
NCT01946243	The feasibility of florbetapir quantitation.	Completed	The overall objective of the study is to assess the feasibility of implementing a quantitative process of florbetapir F 18 scan interpretation.	Alzheimer's disease	4	Interventional
NCT02553928	Comparison of once daily and twice daily dosing on safety and tolerability of memantine in patients with Alzheimer's disease.	Completed	Evaluation of the safety and tolerability of a 20 mg once daily dose of memantine compared with 10 mg given twice daily in patients with dementia of Alzheimer's type and MMSE range 5-18.	Alzheimer's disease	4	Interventional
NCT03724942	Brexipiprazole for the long-term treatment of patients with agitation associated with dementia of the Alzheimer's type.	Completed	To evaluate the safety of brexipiprazole 1 mg or 2 mg after a 14 week treatment regimen for agitation associated with dementia of the Alzheimer's type patients who completed in a double-blind trial, and to investigate the efficacy of brexipiprazole.	Agitation associated with dementia of the Alzheimer's type	4	Interventional
NCT03620981	Brexipiprazole for the treatment of patients with agitation associated with dementia of the Alzheimer's type.	Completed	To evaluate the superiority of brexipiprazole 1 mg or 2 mg over placebo after a 10-week treatment regimen for agitation associated with dementia of the Alzheimer's type in patients who require medication and to investigate the safety of brexipiprazole and identify the optimum dose.	Agitation associated with dementia of the Alzheimer's type	2 and 3	Interventional
NCT03991988	Montelukast therapy on Alzheimer's disease.	Completed	This is a one-year, double-blind placebo-controlled randomised clinical trial that compares montelukast to placebo in individuals with mild cognitive impairment (MCI) and early Alzheimer's disease dementia.	Alzheimer's disease	2	Interventional
NCT03801642	Dapagliflozin in Alzheimer's disease.	Completed		Alzheimer's disease	1 and 2	Interventional

NCT04538066	Bryostatin treatment of moderately severe Alzheimer's disease.	Completed	To evaluate the safety, tolerability and long-term efficacy of bryostatin 1 (hereafter referred to as bryostatin) for the treatment of moderately severe Alzheimer's disease.	Alzheimer's disease	2	Interventional
NCT03101085	S-Equol in Alzheimer's disease 2 trial.	Completed	Does S-equol, a compound that acts like oestrogen in the body, causes an increase in mitochondrial activity.	Alzheimer's disease	1 and 2	Interventional

**Table 4:** Various patents filed against heterocyclics for neurodegenerative disorders

S.No.	Patent number	Receptor involved	Heterocyclic compounds	Structure	Effective against disease	Ref.
1	WO2009136814A1	5-HT6 receptors	3-sulphonyl-6,7,8,9-tetrahydro-pyrazolo[1,5-a]pyrido[4,3-d]-pyrimidines.	<p>Ar substituted aryl or heterocycl R1 hydrogen atom or a substituted lower C1-C3 alkyl R2 hydrogen or a substituted C1-C3 alkyl R3 hydrogen atom substituted C1-C3 alkyl tert-butoxycarbonyl R4 Hydrogen substituted C1-C3 alkynyl</p>	Alzheimer's disease, Huntington's disease, schizophrenia	[44]
3	US7745451B2	5-HT6 receptors	Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine-fused heterocyclic compounds.		Alzheimer's disease, Huntington's disease, schizophrenia	[36]
4	US9102679B2 and US9328120B2	PDE9A inhibition	6-cycloalkyl-pyrazolopyrimidinones.		Treatment of CNS disorders by modulating PDE9A	[7]

A number of heterocyclics are already available against PD and MS which are acting at various sites to increase the level of dopamine by restoring dopaminergic neurons and to decrease CNS inflammation respectively some of which are given in Figure 3 and 4.

Researchers are focused towards the development of a multi target approach to synthesise heterocyclic scaffolds to aim towards new biological targets. Therefore, many researchers are working towards improving the properties of drugs through chemical modifications of the starting structure. Other heterocyclic natural compounds



inspired the design of original structures some of which are even under clinical trials as given in Table 3 and 4, respectively.<sup>43</sup>

## Conclusion

The actual reason underlying neurodegenerative diseases is still a mystery and may involve various environmental factors such as oxidative stress, mitochondrial defects, inflammation, protein degradation, familial history, ageing and abnormal protein accumulation in neuron. The outcomes obtained by various heterocyclics leave a room for some alternative treatments such as herbals. A number of *in vivo* studies and clinical trials reported that a number of herbal plants and their derived medicinal compounds can prevent or alleviate some neurological disorders and their associated symptoms. Based on these reports, the herbal medicines are becoming popular day by day and gaining more attention towards searching new therapies for neurodegenerative diseases thus opening a new platform for researchers.

## Ethics

This study was a secondary analysis based on the currently existing data and did not directly involve with human participants or experimental animals. Therefore, the ethics approval was not required in this paper.

## Acknowledgement

Authors are thankful to Panjab University, Chandigarh College of Pharmacy and Saveetha Institute of Medical and Technical Sciences.

## Conflicts of interest

The authors declare that there is no conflict of interest.

## Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

## Data access

The data that support the findings of this study are available from the corresponding author upon reasonable individual request.

## Author ORCID numbers

Divya Dhawal Bhandari (DDB):  
0000-0002-2813-0267  
Prabhjot Kaur (PK):  
0000-0002-9781-6668  
Hitesh Chopra (HC):  
0000-0001-8867-7603  
Suman Lata (SL):  
0000-0002-2177-7834

## Author contributions

Conceptualisation: HC  
Methodology: DDB, HC  
Data curation: DDB, PK  
Writing - original draft: DDB, HC  
Writing - review and editing: PK, SL

## References

1. Hiremathad A, Piemontese L. Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy. *Neural Regen Res.* 2017 Aug;12(8):1256-61. doi: 10.4103/1673-5374.213541.
2. Rizzi G, Tan RK. Dopamine and Acetylcholine, A circuit point of view in Parkinson's disease. *Front. Neural Circuits.* 2017 Dec 22;11:110. doi: 10.3389/fncir.2017.00110.
3. Delenclos M, Jones DR, McLean PJ, Uitti RJ. Biomarkers in Parkinson's disease: Advances and strategies. *Parkinsonism Relat Disord.* 2016 Jan; 22 Suppl 1(Suppl 1):S106-S110. doi: 10.1016/j.parkreldis.2015.09.048.

4. Kaur P, Sodhi RK. Memory recuperative potential of rifampicin in aluminum chloride-induced dementia: role of pregnane X receptors. *Neuroscience*. 2015 Mar;288:24-36. doi: 10.1016/j.neuroscience.2014.12.033.
5. Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. *Brain Behav*. 2015 Sep;5(9):e00362. doi: 10.1002/brb3.362.
6. Anandhan K, Tamilselvam T, Radhiga S, Rao MM, Essa TM. Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease. *Brain Res*. 2012 Jan 18; 1433: 104-113. doi: 10.1016/j.brainres.2011.11.021.
7. Huang X, Li N, Pu Y, Zhang T, Wang B. Neuroprotective effects of Ginseng phytochemicals: recent perspectives. *Molecules*. 2019 Aug 14;24(16):2939. doi: 10.3390/molecules24162939.
8. Le Witt PA, Fahn S. Levodopa therapy for Parkinson disease a look backward and forward. *Neurology*. 2016 Apr 5;86:S3-S12. doi: 10.1212/WNL.0000000000002509.
9. Zbarsky V, Datla KV, Parkar S, Rai DK, Aruoma OI, Dexter DT. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. *Free Radic Res*. 2005 Oct;39:1119-25. doi: 10.1080/10715760500233113.
10. Singh SK, Srivastav S, Castellani RJ, Plascencia-Villa G, Perry G. Neuroprotective and antioxidant effect of Ginkgo biloba extract against AD and other neurological disorders. *Neurotherapeutics*. 2019 July;16:666-74. doi: 10.1007/s13311-019-00767-8.
11. Liu SM, Li XZ, Huo Y, Lu F. Protective effect of extract of Acanthopanax senticosus harms on dopaminergic neurons in Parkinson's disease mice. *Phytomedicine*. 2012 May 15;19(7):631-8. doi: 10.1016/j.phymed.2012.02.006.
12. Sarrafchi A, Bahmani M, Shirzad H, Rafieian-Kopaei M. Oxidative stress and Parkinson's disease: new hopes in treatment with herbal antioxidants. *Curr Pharm Des*. 2016;22(2):238-46. doi: 10.2174/138161282266151112151653.
13. Fujikawa T, Kanada N, Shimada A, Ogata M, Suzuki I, Hayashi I, et al. Effect of sesamin in Acanthopanax senticosus H ARMS on behavioral dysfunction in rotenone-induced parkinsonian rats. *Biol Pharm Bull*. 2005 Jan;28(1):169-72. doi: 10.1248/bpb.28.169.
14. Beppe GJ, Dongmo AB, Foyet HS, Dimo T, Mihasan M, Hritcu, L. The aqueous extract of *Albizia adianthifolia* leaves attenuates 6-hydroxydopamine-induced anxiety, depression and oxidative stress in rat amygdala. *BMC Complement Altern Med*. 2015 Oct 19;15(1):1-13. doi: 10.1186/s12906-015-0912-0.
15. Banu Z, Fatima SJ, Fatima A, Fatima S, Zohra SF, Sultana T. Phytochemical evaluation and pharmacological screening of Antiparkinson's activity of *Allium sativum* in Swiss/Albino Mice. *IOSRPHR*. 2016 Jun;6(6):1-12.
16. Garcia E, Santana-Martinez R, Silva-Islas CA, Collin-Gonzalez AL, Galvan-Arzate S, Heras Y, Santamaria A. S-allyl cysteine protects against MPTP-induced striatal and nigral oxidative neurotoxicity in mice: participation of Nrf2. *Free Radic Res*. 2014 Feb;48(2):159-67. doi: 10.3109/10715762.2013.857019.
17. Zhang ZJ, Cheang LC, Wang MW, Li GH, Chu IK, Lin ZX et. al. Ethanolic extract of *fructus Alpinia oxyphylla* protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish. *Cell Mol Neurobiol*. 2012 Jan;32(1):27-40. doi: 10.1007/s10571-011-9731-0.
18. Zhang HN, An CN, Zhang HN, Pu XP. Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo. *Neurosci Lett*. 2010 Apr;474(2):99-103. doi: 10.1016/j.neulet.2010.03.016.
19. Shinomol GK, Mythri RB, Srinivas Bharath MM. Bacopa monnieri extract offsets rotenone-induced cytotoxicity in dopaminergic cells and oxidative impairments in mice brain. *Cell mol neurobiol*. 2012 Apr;32(3):455-65. doi: 10.1007/s10571-011-9776-0.
20. Magannavar CV, Avinash SP, Sowmya C. Neuroprotective Activity of *Berberis aristata* against 6-OHDA Induced Parkinson's Disease Model. *FASEBJ*. 2013 Apr;890-16. doi: 10.1096/fasebj.27.1\_supplement.890.16.
21. Nade VS, Kawale LA, Zambre SS, Kapure AB. Neuroprotective potential of *Beta vulgaris* L. in Parkinson's disease. *Indian J Pharmacol*. 2015 Jul-Aug; 47(4):403. doi: 10.4103/0253-7613.161263.
22. Prasanth MI, Sivamaruthi BS, Chaiyasut C, Tencomnao T. A review of the role of green tea (*Camellia sinensis*) in antiphotoaging, stress resistance, neuroprotection, and autophagy. *Nutrients*. 2019 Feb 23;11(2):474. doi: 10.3390/nu11020474.
23. Ren R, Shi C, Cao J, Sun Y, Zhao X, Guo Y et. al. Neuroprotective effects of a standardized flavonoid extract of safflower against neurotoxin-induced cellular and animal models of Parkinson's disease. *Sci Rep*. 2016 Feb 24;6:22135. doi: 10.1038/srep22135.
24. Ju MS, Kim HG, Choi JG, Ryu JH, Hur J, Kim YJ et.al. *Cassiae semen*, a seed of *Cassia obtusifolia*, has neuroprotective effects in Parkinson's disease models. *Food Chem Toxicol*. 2010 Aug-Sep;48(8-9):2037-44. doi: 10.1016/j.fct.2010.05.002.
25. Bagewadi HG, Khan AK. Evaluation of anti-parkinsonian activity of *Elaeocarpus ganitrus* on haloperidol induced Parkinson's disease in mice. *Int J Basic Clin Pharmacol*. 2015 Jan 20;4(1):102-6. doi: 10.5455/2319-2003.ijbcp20150218.
26. Auddy B, Ferreira M, Blasina F, Lafon L, Arredondo F, Dajas F, et.al. Screening of antioxidant activity of three Indian medicinal plants, traditionally used for the management of neurodegenerative diseases. *J Ethnopharmacol*. 2003 Feb;84(2-3):131-8. doi: 10.1016/s0378-8741(02)00322-7.
27. Alam G, Edler M, Burchfield S, Richardson JR. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss. *Neurotoxicology*. 2017 May;60:99-106. doi: 10.1016/j.neuro.2017.03.008.
28. Zou YP, Lu YH, Wei DZ. Protective effects of a flavonoid-rich extract of *Hypericum perforatum* L. against hydrogen peroxide-induced apoptosis in PC12 cells. *Phytother Res*. 2010 Jan;24 Suppl 1:S6-S10. doi: 10.1002/ptr.2852.
29. Kang X, Chen J, Xu Z, Li H, Wang B. Protective effects of Ginkgo biloba extract on paraquat-induced apoptosis of PC12 cells. *Toxicol In Vitro*. 2007 Sep;21(6):1003-9. doi: 10.1016/j.tiv.2007.02.004.
30. Muroyama A, Fujita A, Lv C, Kobayashi S, Fukuyama Y, Mitsumoto Y. Magnolol protects against MPTP/MPP<sup>+</sup>-induced toxicity via inhibition of oxidative stress in in vivo and in vitro models of Parkinson's disease. *Parkinsons Dis*. 2012;2012:985157. doi: 10.1155/2012/985157.
31. Kim HG, Ju MS, Shim JS, Kim MC, Lee SH, Huh Y, et al. Mulberry fruit protects dopaminergic neurons in toxin-induced Parkinson's disease models. *Br J Nutr*. 2010 Jul;104(1):8-16. doi: 10.1017/S0007114510000218.
32. Cao BY, Yang YP, Luo WF, Mao CJ, Han R, Sun X et.al. Paeoniflorin, a potent natural compound, protects PC12 cells from MPP<sup>+</sup> and acidic damage via autophagic pathway. *J Ethnopharmacol*. 2010 Aug 19;131(1):122-9. doi: 10.1016/j.jep.2010.06.009.

33. Hu S, Han R, Mak S, Han Y. Protection against 1-methyl-4-phenylpyridinium ion (MPP<sup>+</sup>)-induced apoptosis by water extract of ginseng (*Panax ginseng* C.A. Meyer) in SH-SY5Y cells. *J Ethnopharmacol.* 2011 Apr 26;135(1):34-42. doi: 10.1016/j.jep.2011.02.017.
34. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of *Withania somnifera* (ashwagandha): a review. *Altern Med Rev.* 2000 Aug;5(4):334-46. PMID: 10956379.
35. Schliebs R, Liebmann A, Bhattacharya SK, Kumar A, Ghosal S, Bigl V. Systemic administration of defined extracts from *Withania somnifera* (Indian Ginseng) and Shilajit differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. *Neurochem Int.* 1997 Feb;30(2):181-90. doi: 10.1016/s0197-0186(96)00025-3.
36. Nagashayana N, Sankarankutty P, Nampoothiri MR, Mohan PK, Mohanakumar KP. Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease. *J Neurol Sci.* 2000 Jun 15;176(2):124-7. doi: 10.1016/s0022-510x(00)00329-4.
37. Lü JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. *Curr Vasc Pharmacol.* 2009 Jul;7(3):293-302. doi: 10.2174/157016109788340767.
38. Ju MS, Lee P, Kim HG, Lee KY, Hur J, Cho SH et.al. Protective effects of standardized *Thuja orientalis* leaves against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. *Toxicol In Vitro.* 2010 Apr;24(3):759-65. doi: 10.1016/j.tiv.2009.12.026.
39. Kosaraju J, Chinni S, Roy PD, Kannan E, Antony AS, Kumar MN. Neuroprotective effect of *Tinospora cordifolia* ethanol extract on 6-hydroxy dopamine induced Parkinsonism. *Indian J Pharmacol.* 2014 Mar-Apr;46(2):176-80. doi: 10.4103/0253-7613.129312.
40. Shim JS, Kim HG, Ju MS, Choi JG, Jeong SY, Oh MS. Effects of the hook of *Uncaria rhynchophylla* on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease. *J Ethnopharmacol.* 2009 Nov 12;126(2):361-5. doi: 10.1016/j.jep.2009.08.023.
41. Brahmachari S, Pahan K. Sodium benzoate, a food additive and a metabolite of cinnamon, modifies T cells at multiple steps and inhibits adoptive transfer of experimental allergic encephalomyelitis. *J Immunol.* 2007 Jul 1;179(1):275-83. doi: 10.4049/jimmunol.179.1.275.
42. Prakash J, Chouhan S, Yadav SK, Westfall S, Rai SN, Singh SP. *Withania somnifera* alleviates parkinsonian phenotypes by inhibiting apoptotic pathways in dopaminergic neurons. *Neurochem Res.* 2014 Dec;39(12):2527-36. doi: 10.1007/s11064-014-1443-7.
43. Kaur P, Sharma V. Prospective plant based anticancer lead molecules. *Curr Top Med Chem.* 2018;18(30):2567-83. doi: 10.2174/1568026619666181224101132.
44. Nematollahi M, Majdinasab N, Fakharzadeh L, Namjooyan F, Latifi S, Pouretezad M. The effect of *Nigella sativa* seeds on the muscle spasticity of lower limbs in patients with multiple sclerosis. *Iran J Neurol.* 2013;12:16. doi: 10.4103/2225-4110.136543.